Last reviewed · How we verify
administration of dexamethasone intravenously
administration of dexamethasone intravenously is a Small molecule drug developed by Pontificia Universidad Catolica de Chile. It is currently in Phase 1 development.
At a glance
| Generic name | administration of dexamethasone intravenously |
|---|---|
| Sponsor | Pontificia Universidad Catolica de Chile |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
- A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer (PHASE2)
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (PHASE1)
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- administration of dexamethasone intravenously CI brief — competitive landscape report
- administration of dexamethasone intravenously updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI
Frequently asked questions about administration of dexamethasone intravenously
What is administration of dexamethasone intravenously?
administration of dexamethasone intravenously is a Small molecule drug developed by Pontificia Universidad Catolica de Chile.
Who makes administration of dexamethasone intravenously?
administration of dexamethasone intravenously is developed by Pontificia Universidad Catolica de Chile (see full Pontificia Universidad Catolica de Chile pipeline at /company/pontificia-universidad-catolica-de-chile).
What development phase is administration of dexamethasone intravenously in?
administration of dexamethasone intravenously is in Phase 1.